vs
博士伦（BLCO）与利氏兄弟拍卖行（RBA）财务数据对比。点击上方公司名可切换其他公司
博士伦的季度营收约是利氏兄弟拍卖行的1.2倍（$1.4B vs $1.2B），利氏兄弟拍卖行净利率更高（9.1% vs -4.1%，领先13.2%），博士伦同比增速更快（9.8% vs 5.4%），利氏兄弟拍卖行自由现金流更多（$186.5M vs $60.0M），过去两年博士伦的营收复合增速更高（13.1% vs 6.3%）
博士伦是知名眼健康产品企业，总部位于加拿大安大略省沃恩市，是全球规模最大的隐形眼镜、镜片护理产品、眼科药品、人工晶体及其他眼科手术产品供应商之一。品牌1853年由验光师约翰·鲍什与合伙人亨利·朗姆在美国纽约罗切斯特创立，曾是美国历史最悠久的持续运营企业之一，2013年被整体收购。
利氏兄弟拍卖行（股票代码RBA）是全球知名的工业资产拍卖服务商，注册地位于加拿大，属公开上市企业，总部设在美国伊利诺伊州韦斯特切斯特，普通股同时在多伦多证券交易所与纽约证券交易所挂牌交易。
BLCO vs RBA — 直观对比
营收规模更大
BLCO
是对方的1.2倍
$1.2B
营收增速更快
BLCO
高出4.4%
5.4%
净利率更高
RBA
高出13.2%
-4.1%
自由现金流更多
RBA
多$126.5M
$60.0M
两年增速更快
BLCO
近两年复合增速
6.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $1.2B |
| 净利润 | $-58.0M | $109.7M |
| 毛利率 | — | — |
| 营业利润率 | 8.0% | 14.7% |
| 净利率 | -4.1% | 9.1% |
| 营收同比 | 9.8% | 5.4% |
| 净利润同比 | -1833.3% | -7.4% |
| 每股收益（稀释后） | $-0.16 | $0.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLCORBA
| Q4 25 | $1.4B | $1.2B | ||
| Q3 25 | $1.3B | $1.1B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.1B | $1.1B | ||
| Q4 24 | $1.3B | $1.1B | ||
| Q3 24 | $1.2B | $981.8M | ||
| Q2 24 | $1.2B | $1.1B | ||
| Q1 24 | $1.1B | $1.1B |
净利润BLCORBA
| Q4 25 | $-58.0M | $109.7M | ||
| Q3 25 | $-28.0M | $95.5M | ||
| Q2 25 | $-62.0M | $109.8M | ||
| Q1 25 | $-212.0M | $113.4M | ||
| Q4 24 | $-3.0M | $118.5M | ||
| Q3 24 | $4.0M | $76.1M | ||
| Q2 24 | $-151.0M | $111.1M | ||
| Q1 24 | $-167.0M | $107.4M |
营业利润率BLCORBA
| Q4 25 | 8.0% | 14.7% | ||
| Q3 25 | 7.4% | 14.5% | ||
| Q2 25 | -0.9% | 15.9% | ||
| Q1 25 | -7.3% | 17.1% | ||
| Q4 24 | 6.8% | 18.1% | ||
| Q3 24 | 3.6% | 15.6% | ||
| Q2 24 | 2.1% | 18.4% | ||
| Q1 24 | 0.5% | 18.7% |
净利率BLCORBA
| Q4 25 | -4.1% | 9.1% | ||
| Q3 25 | -2.2% | 8.7% | ||
| Q2 25 | -4.9% | 9.3% | ||
| Q1 25 | -18.6% | 10.2% | ||
| Q4 24 | -0.2% | 10.4% | ||
| Q3 24 | 0.3% | 7.8% | ||
| Q2 24 | -12.4% | 10.1% | ||
| Q1 24 | -15.2% | 10.1% |
每股收益（稀释后）BLCORBA
| Q4 25 | $-0.16 | $0.53 | ||
| Q3 25 | $-0.08 | $0.43 | ||
| Q2 25 | $-0.18 | $0.53 | ||
| Q1 25 | $-0.60 | $0.55 | ||
| Q4 24 | $-0.00 | $0.58 | ||
| Q3 24 | $0.01 | $0.36 | ||
| Q2 24 | $-0.43 | $0.54 | ||
| Q1 24 | $-0.48 | $0.53 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $383.0M | $531.5M |
| 总债务越低越好 | $5.0B | $2.3B |
| 股东权益账面价值 | $6.4B | $5.6B |
| 总资产 | $14.0B | $12.1B |
| 负债/权益比越低杠杆越低 | 0.78× | 0.42× |
8季度趋势，按日历期对齐
现金及短期投资BLCORBA
| Q4 25 | $383.0M | $531.5M | ||
| Q3 25 | $310.0M | $674.7M | ||
| Q2 25 | $266.0M | $710.2M | ||
| Q1 25 | $202.0M | $578.1M | ||
| Q4 24 | $305.0M | $533.9M | ||
| Q3 24 | $329.0M | $650.7M | ||
| Q2 24 | $285.0M | $599.5M | ||
| Q1 24 | $315.0M | $462.8M |
总债务BLCORBA
| Q4 25 | $5.0B | $2.3B | ||
| Q3 25 | $5.0B | $2.6B | ||
| Q2 25 | $5.0B | $2.6B | ||
| Q1 25 | $4.8B | $2.6B | ||
| Q4 24 | $4.8B | $2.6B | ||
| Q3 24 | $4.6B | $2.7B | ||
| Q2 24 | $4.6B | $2.8B | ||
| Q1 24 | $4.6B | $2.9B |
股东权益BLCORBA
| Q4 25 | $6.4B | $5.6B | ||
| Q3 25 | $6.4B | $5.5B | ||
| Q2 25 | $6.4B | $5.5B | ||
| Q1 25 | $6.4B | $5.3B | ||
| Q4 24 | $6.5B | $5.2B | ||
| Q3 24 | $6.6B | $5.2B | ||
| Q2 24 | $6.5B | $5.2B | ||
| Q1 24 | $6.7B | $5.1B |
总资产BLCORBA
| Q4 25 | $14.0B | $12.1B | ||
| Q3 25 | $13.8B | $12.2B | ||
| Q2 25 | $13.8B | $12.2B | ||
| Q1 25 | $13.4B | $11.9B | ||
| Q4 24 | $13.5B | $11.8B | ||
| Q3 24 | $13.5B | $11.9B | ||
| Q2 24 | $13.3B | $12.1B | ||
| Q1 24 | $13.3B | $12.0B |
负债/权益比BLCORBA
| Q4 25 | 0.78× | 0.42× | ||
| Q3 25 | 0.77× | 0.47× | ||
| Q2 25 | 0.77× | 0.47× | ||
| Q1 25 | 0.76× | 0.50× | ||
| Q4 24 | 0.74× | 0.50× | ||
| Q3 24 | 0.70× | 0.52× | ||
| Q2 24 | 0.71× | 0.55× | ||
| Q1 24 | 0.69× | 0.58× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $136.0M | $255.2M |
| 自由现金流经营现金流 - 资本支出 | $60.0M | $186.5M |
| 自由现金流率自由现金流/营收 | 4.3% | 15.5% |
| 资本支出强度资本支出/营收 | 5.4% | 5.7% |
| 现金转化率经营现金流/净利润 | — | 2.33× |
| 过去12个月自由现金流最近4个季度 | $-66.0M | $719.2M |
8季度趋势，按日历期对齐
经营现金流BLCORBA
| Q4 25 | $136.0M | $255.2M | ||
| Q3 25 | $137.0M | $239.7M | ||
| Q2 25 | $35.0M | $326.5M | ||
| Q1 25 | $-25.0M | $156.8M | ||
| Q4 24 | $22.0M | $184.5M | ||
| Q3 24 | $154.0M | $285.4M | ||
| Q2 24 | $15.0M | $337.3M | ||
| Q1 24 | $41.0M | $124.8M |
自由现金流BLCORBA
| Q4 25 | $60.0M | $186.5M | ||
| Q3 25 | $63.0M | $188.5M | ||
| Q2 25 | $-54.0M | $241.7M | ||
| Q1 25 | $-135.0M | $102.5M | ||
| Q4 24 | $-70.0M | $127.9M | ||
| Q3 24 | $94.0M | $248.5M | ||
| Q2 24 | $-57.0M | $308.6M | ||
| Q1 24 | $-26.0M | $79.6M |
自由现金流率BLCORBA
| Q4 25 | 4.3% | 15.5% | ||
| Q3 25 | 4.9% | 17.3% | ||
| Q2 25 | -4.2% | 20.4% | ||
| Q1 25 | -11.9% | 9.2% | ||
| Q4 24 | -5.5% | 11.2% | ||
| Q3 24 | 7.9% | 25.3% | ||
| Q2 24 | -4.7% | 28.2% | ||
| Q1 24 | -2.4% | 7.5% |
资本支出强度BLCORBA
| Q4 25 | 5.4% | 5.7% | ||
| Q3 25 | 5.8% | 4.7% | ||
| Q2 25 | 7.0% | 7.2% | ||
| Q1 25 | 9.7% | 4.9% | ||
| Q4 24 | 7.2% | 5.0% | ||
| Q3 24 | 5.0% | 3.8% | ||
| Q2 24 | 5.9% | 2.6% | ||
| Q1 24 | 6.1% | 4.2% |
现金转化率BLCORBA
| Q4 25 | — | 2.33× | ||
| Q3 25 | — | 2.51× | ||
| Q2 25 | — | 2.97× | ||
| Q1 25 | — | 1.38× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | 38.50× | 3.75× | ||
| Q2 24 | — | 3.04× | ||
| Q1 24 | — | 1.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLCO
| Overthe Counter Products | $489.0M | 35% |
| Pharmaceuticals | $378.0M | 27% |
| Other | $263.0M | 19% |
| Surgical | $249.0M | 18% |
| Brandedand Other Generic Products | $14.0M | 1% |
| Other Revenues | $3.0M | 0% |
| Pharmaceutical Products | $2.0M | 0% |
RBA
| Buyer Revenue | $577.2M | 48% |
| Seller Revenue | $255.2M | 21% |
| CA | $199.0M | 17% |
| Other | $124.7M | 10% |
| AU | $47.3M | 4% |
